A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

NCT04227847 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions

DRUG: SEA-CD70
DRUG: azacitidine
DRUG: Venetoclax

Sponsor

Seagen, a wholly owned subsidiary of Pfizer